Aims Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐
oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs) …

New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …

Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …

Voxelotor (Oxbryta™) is a haemoglobin S polymerization inhibitor that has been developed
for the treatment of sickle cell disease. In November 2019, voxelotor received its first global …

Objective: To review the pharmacological characteristics, clinical evidence, and place in
therapy of voxelotor for the treatment of sickle cell disease (SCD). Data Sources: A …

Background For decades, patients with sickle cell disease have had only a limited number of
therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin …

Sickle cell disease, despite its recognition as a severely debilitating genetic condition
affecting hundreds of thousands of neonates throughout the world each year, was not a …

Background Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects
millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as …

A major driver of the pathophysiology of sickle cell disease (SCD) is polymerization of
deoxygenated haemoglobin S (HbS), which leads to sickling and destruction of red blood …